Luis Calderón – General Manager, Alexion Mexico
Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the authorities to ensure adequate regulation is put…
Alexion is a global biopharmaceutical company that combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rare diseases. Alexion scientists are among the first in the world to unlock the therapeutic potential of inhibiting terminal complement, a group of proteins that play an important role in the body’s immune response and can destroy healthy tissue in certain patients. Alexion discovered and developed Soliris® (eculizumab), a first-in-class terminal complement inhibitor, approved in the United States, Canada, European Union, Australia, and Japan as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH). Alexion is working urgently to investigate Soliris and additional biopharmaceuticals as treatments for patients with other rare and severe diseases, including cancer.
Contact details
Alexion
Paseo de los Tamarindos 90
Torre 1 Piso 6 Oficina A
Col. Bosque de la Lomas, Del. Cuajimalpa,
C.P. 05120, México DF
MEXICO
Tel: +52 (55) 5047 1500
Website: http://alxn.com/
Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the authorities to ensure adequate regulation is put…
Healthcare should not be seen as an expenditure, but rather as an investment. Mexico’s former minister of health and current dean at the Harvard T.H. Chan School of Public Health…
Mr Carlos Jimenez of B. Braun Aesculap sat down with us and shared his personal beliefs on Mexico’s market potential for medical equipment, how the country can create more momentum…
Brothers Juan José and Andrés Aguirre Salazar of Grupo Bruluart talk about the company’s most important milestones and how they are institutionalizing the family business to prepare the firm for…
Clinical research and access are the name of the game. The Executive Director of the association bringing together the most important research-based pharmaceutical companies discusses how the association has stepped…
The genomic revolution represents a before and after in the field of medicine. Sistemas Genómicos has understood this back in 1998 and today is the largest private organization offering DNA…
The general manager for Cegedim Mexico, Central America and the Caribbean discusses how the company is diversifying its product portfolio to tap into new business segments and attend new clients…
Boehringer Ingelheim is turning 130 in 2015. Miguel Salazar, president and country managing director for Mexico, explains how he is steering the company to bypass the currents of the ever-changing…
‘Health is the milestone of any society’. The former minister of health and former dean of Mexico’s most important university discusses the vision behind the creation of thought-leading institutions such…
Besides protecting the health of Mexicans, COFEPRIS today offers an important value-added to the investment community: predictability. The organization’s commissioner shares the astonishing results of his last three years of…
Biograft is the first private tissue bank in Mexico meeting the increasing demand for implants of human musculoskeletal tissue. The general director and founder discusses the vision behind the creation…
Merck is getting “Fit for 2018”. Pedro Galvis, the company’s managing director for Mexico, discusses how the company’s transformation program, implemented in 2012, is ensuring future growth and how Mexico’s…
Novo Nordisk’s market access and public affairs director discusses the state of diabetes management in Mexico, highlighting the government’s recent commitment to tackle this public health issue and the company’s…
See our Cookie Privacy Policy Here
